Landiolol Hydrochloride
FDA-approved product (powder, intravenous), marketed as Rapiblyk.
- Registered studies
- 6
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Atrial fibrillation
- Atrial flutter
- Supraventricular tachycardia
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Beta blocking agents, selective
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA52.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis41.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
6registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Landiolol Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome60.5% AI-predicted activityagainst E. coli50+ registered studies
- PlecanatideExisting use: Constipation60.1% AI-predicted activityagainst E. coli15 registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia60.0% AI-predicted activityagainst E. coli41 registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more59.6% AI-predicted activityagainst E. coli50+ registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma59.6% AI-predicted activityagainst E. coli2 registered studies
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances59.5% AI-predicted activityagainst E. coli50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more59.4% AI-predicted activityagainst E. coli5 registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst E. coli50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more59.0% AI-predicted activityagainst E. coli50+ registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more58.8% AI-predicted activityagainst E. coli10 registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency58.8% AI-predicted activityagainst E. coli7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
NCT05084118 · start 2021-10-21
Registered record
- Registry ID
- NCT05084118
- Conditions
- Atrial Fibrillation; Postoperative Complications
- Interventions
- Landiolol HCl; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Unknown
- Start
- 2021-10-21
- Completion
- 2024-06-01
- Enrolment
- 164
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation; Postoperative ComplicationsInterventionLandiolol HCl; PlaceboPhasePhase 3Registry statusUnknownPrevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery
NCT04607122 · start 2021-01-27
Registered record
- Registry ID
- NCT04607122
- Conditions
- Atrial Fibrillation; Cardiac Surgery
- Interventions
- Landiolol; Saline
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2021-01-27
- Completion
- 2023-07-22
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtrial Fibrillation; Cardiac SurgeryInterventionLandiolol; SalinePhasePhase 3Registry statusCompletedLong-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers
NCT01741519 · start 2012-12
Registered record
- Registry ID
- NCT01741519
- Conditions
- Healthy
- Interventions
- LDLL600; Brevibloc
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-12
- Completion
- 2013-01
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionLDLL600; BreviblocPhasePhase 1Registry statusCompletedPilot Study of ONO-1101 in Patients Scheduled for Multi-slice CT
NCT00311038 · start 2006-04
Registered record
- Registry ID
- NCT00311038
- Conditions
- Coronary Artery Disease
- Interventions
- ONO-1101
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-04
- Completion
- Not recorded
- Enrolment
- 90
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCoronary Artery DiseaseInterventionONO-1101PhasePhase 2Registry statusCompletedControlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan
NCT00212654 · start 2001-06
Registered record
- Registry ID
- NCT00212654
- Conditions
- Postoperative Supraventricular Tachyarrythmia
- Interventions
- ONO-1101
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2001-06
- Completion
- Not recorded
- Enrolment
- 165
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative Supraventricular TachyarrythmiaInterventionONO-1101PhasePhase 2 / Phase 3Registry statusCompletedControlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan
NCT00212680 · start 1996-12
Registered record
- Registry ID
- NCT00212680
- Conditions
- Postoperative Supraventricular Tachyarrythmia
- Interventions
- ONO-1101
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1996-12
- Completion
- Not recorded
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative Supraventricular TachyarrythmiaInterventionONO-1101PhasePhase 2Registry statusCompleted